Nanoparticle technologies are significantly impacting the development of both therapeutic
and diagnostic agents. At the intersection between treatment and diagnosis, interest has …

Alpha-emitters are radionuclides that decay through the emission of high linear energy
transfer α-particles and possess favorable pharmacologic profiles for cancer treatment …

Drug delivery technologies represent a vast and vital area of Research and Development.
The demand for innovative drug delivery systems continues to grow, and this growth …

The effectiveness of targeted α-therapy (TAT) can be explained by the properties of α-
particles. Alpha particles are helium nuclei and are~ 8,000 times larger than β−-particles …

Targeted alpha therapy is an oncological treatment, where cytotoxic doses of alpha radiation
are locally delivered to tumor cells, while the surrounding healthy tissue is minimally …

α-Emitting radionuclides have been approved for cancer treatment since 2013, with
increasing degrees of success. Despite this clinical utility, little is known regarding the …

Targeted alpha-particle therapy (TAT) aims to selectively deliver radionuclides emitting α-
particles (cytotoxic payload) to tumors by chelation to monoclonal antibodies, peptides or …

It has been proven and confirmed in numerous repeated tests, that the use of a combination
of several therapeutic methods gives much better treatment results than in the case of …

The 7.2-h half life radiohalogen 211At offers many potential advantages for targeted α-
particle therapy; however, its use for this purpose is constrained by its limited availability …

Small cell lung cancer (SCLC) is a neuroendocrine tumor with a high degree of malignancy.
Due to limited treatment options, patients with SCLC have a poor prognosis. We have found …